257 related articles for article (PubMed ID: 20302025)
21. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Petrioli R; Sabatino M; Fiaschi AI; Marsili S; Pozzessere D; Messinese S; Correale P; Civitelli S; Tanzini G; Tani F; De Martino A; Marzocca G; Lorenzi M; Giorgi G; Francini G
Br J Cancer; 2004 Jan; 90(2):306-9. PubMed ID: 14735168
[TBL] [Abstract][Full Text] [Related]
22. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
23. Mitomycin C and UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer.
Michalaki V; Gennatas S; Gennatas C
J BUON; 2010; 15(2):270-3. PubMed ID: 20658720
[TBL] [Abstract][Full Text] [Related]
24. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Carmichael J; Popiela T; Radstone D; Falk S; Borner M; Oza A; Skovsgaard T; Munier S; Martin C
J Clin Oncol; 2002 Sep; 20(17):3617-27. PubMed ID: 12202662
[TBL] [Abstract][Full Text] [Related]
25. Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
Mizushima T; Tamagawa H; Matsuda C; Murata K; Fukunaga M; Ota H; Hasegawa J; Tsujie M; Fukuzaki T; Hata T; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Oncology; 2015; 89(3):152-8. PubMed ID: 25967649
[TBL] [Abstract][Full Text] [Related]
26. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
[TBL] [Abstract][Full Text] [Related]
27. Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Chayahara N; Tamura T; Yamamori M; Kadowaki Y; Okuno T; Miki I; Tsuda M; Nishisaki H; Maeda T; Inoue Y; Okumura K; Azuma T; Kasuga M; Sakaeda T; Hirai M
Am J Clin Oncol; 2009 Feb; 32(1):56-60. PubMed ID: 19194126
[TBL] [Abstract][Full Text] [Related]
28. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Meropol NJ; Sonnichsen DS; Birkhofer MJ; Ferreira I; Noel D
Cancer Chemother Pharmacol; 1999; 43(3):221-6. PubMed ID: 9923552
[TBL] [Abstract][Full Text] [Related]
29. [Compliance of oral UFT plus leucovorin adjuvant chemotherapy in patients who underwent curative resection for colorectal cancer].
Tsunoda A; Nakao K; Watanabe M
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1065-8. PubMed ID: 20567109
[TBL] [Abstract][Full Text] [Related]
30. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
[TBL] [Abstract][Full Text] [Related]
31. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Nagase H; Uchida J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):285-91. PubMed ID: 22752215
[TBL] [Abstract][Full Text] [Related]
32. Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.
Méndez M; Alfonso PG; Pujol E; González E; Castañon C; Cerezuela P; López-Mateos Y; Cruz JJ
Invest New Drugs; 2005 Jun; 23(3):243-51. PubMed ID: 15868381
[TBL] [Abstract][Full Text] [Related]
33. Survival benefit of oral tegafur/uracil and leucovorin as a first line therapy for elderly patients with advanced or metastatic colorectal cancer.
Murata K; Yamamoto H; Fukunaga M; Kato T; Ohnishi T; Uemura Y; Ohta H; Kimura F; Ohue M; Nezu R; Sekimoto M; Ikeda M; Mizushimaz T; Doki Y; Mori M;
Hepatogastroenterology; 2014; 61(129):94-8. PubMed ID: 24895801
[TBL] [Abstract][Full Text] [Related]
34. A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
Ishida H; Miyake Y; Fukunaga M; Watanabe Y; Kato T; Takemoto H; Furukawa H
Jpn J Clin Oncol; 2009 Sep; 39(9):601-5. PubMed ID: 19535386
[TBL] [Abstract][Full Text] [Related]
35. Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
Okabayashi K; Hasegawa H; Ishii Y; Endo T; Ochiai H; Kubota T; Kitagawa Y
Cancer Chemother Pharmacol; 2009 Feb; 63(3):501-7. PubMed ID: 18461329
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
[TBL] [Abstract][Full Text] [Related]
37. Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.
Sheikh HY; Valle JW; Waddell T; Palmer K; Wilson G; Sjursen A; Craven O; Swindell R; Saunders MP
Br J Cancer; 2008 Aug; 99(4):577-83. PubMed ID: 18682717
[TBL] [Abstract][Full Text] [Related]
38. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
Bajetta E; Di Bartolomeo M; Buzzoni R; Mariani L; Zilembo N; Ferrario E; Lo Vullo S; Aitini E; Isa L; Barone C; Jacobelli S; Recaldin E; Pinotti G; Iop A
Br J Cancer; 2007 Feb; 96(3):439-44. PubMed ID: 17245343
[TBL] [Abstract][Full Text] [Related]
39. Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.
Alkis N; Demirci U; Benekli M; Yilmaz U; Isikdogan A; Sevinc A; Ozdemir NY; Koca D; Yetisyigit T; Kaplan MA; Uncu D; Unek T; Gumus M
J BUON; 2011; 16(1):80-3. PubMed ID: 21674854
[TBL] [Abstract][Full Text] [Related]
40. Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma.
Hoff PM; Pazdur R
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):48-50. PubMed ID: 10442361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
